Skip to main content
Clinical Trials/NCT03226652
NCT03226652
Completed
Not Applicable

Heart Function in Patients Assessed for Sleep Disordered Breathing (SDB)

Imperial College London1 site in 1 country101 target enrollmentJuly 24, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure With Preserved Ejection Fraction
Sponsor
Imperial College London
Enrollment
101
Locations
1
Primary Endpoint
Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study aims to determine the prevalence and prognosis of heart failure with preserved ejection function (HFpEF) among patients being assessed for sleep disordered breathing (SDB).

Detailed Description

Patients with sleep disordered breathing (SDB) and those with heart failure with preserved ejection fraction (HFpEF) share similar characteristics. Increasing age, hypertension, obesity, diabetes mellitus and atrial fibrillation are well recognised links in both groups. It also known that SDB is common in patients with heart failure, both with reduced and preserved ejection fraction. It is therefore hypothesised that among patients being referred for SDB assessment, we can identify a group with unrecognised HFpEF.

Registry
clinicaltrials.gov
Start Date
July 24, 2017
End Date
April 1, 2019
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged ≥40 years and referred for respiratory polygraphy

Exclusion Criteria

  • Previous diagnosis of Heart Failure
  • Treated sleep disordered breathing

Outcomes

Primary Outcomes

Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB)

Time Frame: Baseline

The diagnosis of HFpEF was established using criteria set out in the European Society for Cardiology (ESC) guidelines based on clinical symptoms and/or signs, biomarker analysis (NT-proBNP) and evidence of structural cardiac remodeling or diastolic dysfunction on transthoracic echocardiography.

Study Sites (1)

Loading locations...

Similar Trials